Skip to main content
Fig. 5 | Retrovirology

Fig. 5

From: Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo

Fig. 5

Ruxolitinib does not alter apoptosis threshold or CD69 expression in the presence of ingenol-3,20-dibenzoate. Ruxolitinib (100 nM) did not significantly alter the percentage of resting CD4+ T cells expressing activated caspase 3 (a) or expression of CD69 (represented as the mean florescence intensity or MFI with the total percentage of cells in each culture condition expressing CD69 within each bar; b) in the presence of ingenol-3,20-dibenzoate (ingenol DB). Mean values and standard deviation are shown for four independent experiments using resting CD4+ T cells from aviremic ART-treated participants (n = 4)

Back to article page